What's more, a study revealed that MeCP2 transcription level is higher in oestrogen receptor‐positive (ER+) breast cancer than in oestrogen‐negative(ER−) breast cancer, and the activation of ERα inhibits EMT of breast cancer.21, 22. Here, MECP2 is linked to breast carcinoma.